Free Trial

Biofrontera (BFRIW) Financials

Biofrontera logo
$0.0014 0.00 (0.00%)
As of 11/2/2026
Annual Income Statements for Biofrontera

Annual Income Statements for Biofrontera

This table shows Biofrontera's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-11 -38 -0.64 -20 -18 -11
Consolidated Net Income / (Loss)
-11 -38 -0.64 -20 -18 -11
Net Income / (Loss) Continuing Operations
-11 -38 -0.64 -20 -18 -11
Total Pre-Tax Income
-11 -38 -0.61 -20 -18 -11
Total Operating Income
-9.61 -25 -19 -23 -17 -11
Total Gross Profit
19 24 29 17 19 31
Total Revenue
19 24 29 34 37 42
Operating Revenue
19 24 29 34 37 42
Total Cost of Revenue
0.00 0.00 0.00 17 19 11
Operating Cost of Revenue
- - - 17 19 11
Total Operating Expenses
28 49 47 39 36 42
Selling, General & Admin Expense
18 37 35 39 34 38
Research & Development Expense
- - 0.00 0.08 2.09 3.72
Total Other Income / (Expense), net
-1.32 -12 18 2.56 -0.53 0.84
Interest Expense
2.87 0.34 0.20 0.00 0.32 0.00
Interest & Investment Income
- 0.00 1.75 -7.89 -2.05 -0.45
Other Income / (Expense), net
1.55 -12 16 10 1.84 1.29
Income Tax Expense
0.06 0.06 0.03 0.01 0.02 0.03
Basic Earnings per Share
($479.48) ($4.28) ($0.61) ($13.02) ($3.22) ($1.04)
Weighted Average Basic Shares Outstanding
22.92M 8.81M 1.06M 1.55M 5.52M 10.17M
Diluted Earnings per Share
($479.48) - ($0.61) ($13.02) ($3.22) ($1.04)
Weighted Average Diluted Shares Outstanding
22.92M 8.81M 1.06M 1.55M 5.52M 10.17M
Weighted Average Basic & Diluted Shares Outstanding
22.92M 8.81M 26.70M 5.09M 8.87M 11.65M

Quarterly Income Statements for Biofrontera

This table shows Biofrontera's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75 -0.60 -6.42
Consolidated Net Income / (Loss)
-10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75 -0.60 -6.42
Net Income / (Loss) Continuing Operations
-10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75 -0.60 -6.42
Total Pre-Tax Income
-10 -0.24 -5.67 -1.40 -4.20 -5.30 -6.64 5.64 -4.75 -0.58 -6.42
Total Operating Income
-5.47 -5.07 -4.96 -1.71 -4.55 -5.08 -6.28 4.56 -4.32 -0.52 -6.50
Total Gross Profit
3.80 3.50 4.14 7.29 5.32 6.39 4.94 14 7.97 9.59 6.75
Total Revenue
7.91 7.84 9.01 13 8.59 9.03 6.99 17 10 12 9.07
Total Cost of Revenue
4.12 4.34 4.88 5.27 3.27 2.64 2.05 3.01 2.12 2.41 2.32
Operating Cost of Revenue
4.12 4.34 4.88 5.27 3.27 2.64 2.05 3.01 2.12 2.41 2.32
Total Operating Expenses
9.26 8.57 9.10 9.00 9.87 11 11 9.54 12 10 13
Selling, General & Admin Expense
9.25 7.95 8.43 8.22 8.66 11 10 8.75 11 9.67 12
Research & Development Expense
0.02 0.62 0.67 0.78 1.21 0.87 0.85 0.79 0.90 0.45 0.45
Other Operating Expenses / (Income)
- - - - - 0.00 0.00 - 0.39 0.00 0.31
Total Other Income / (Expense), net
-4.97 4.83 -0.71 0.31 0.34 -0.22 -0.37 1.08 -0.43 -0.06 0.08
Interest & Investment Income
-1.40 -0.61 0.01 -0.04 -0.11 -0.11 -0.11 -0.12 -0.13 -0.13 -0.12
Other Income / (Expense), net
-3.25 5.44 -0.71 0.36 0.45 -0.11 -0.26 1.20 -0.31 0.07 0.20
Income Tax Expense
0.00 0.02 0.00 -0.00 -0.00 0.02 0.01 -0.00 0.00 0.02 0.00
Basic Earnings per Share
($2.88) ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41) ($0.05) ($0.42)
Weighted Average Basic Shares Outstanding
3.62M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M 12.92M 15.28M
Diluted Earnings per Share
($2.88) ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41) ($0.05) ($0.42)
Weighted Average Diluted Shares Outstanding
3.62M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M 12.92M 15.28M
Weighted Average Basic & Diluted Shares Outstanding
5.09M 5.54M 7.75M 8.87M 9.45M 10.67M 11.65M 11.65M 12.80M 14.85M 17.95M

Annual Cash Flow Statements for Biofrontera

This table details how cash moves in and out of Biofrontera's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.83 16 -7.33 -16 4.56 0.49
Net Cash From Operating Activities
-12 -27 -16 -25 -10 -13
Net Cash From Continuing Operating Activities
-12 -27 -16 -25 -10 -13
Net Income / (Loss) Continuing Operations
-11 -38 -0.64 -20 -18 -11
Consolidated Net Income / (Loss)
-11 -38 -0.64 -20 -18 -11
Depreciation Expense
0.14 0.12 0.10 0.09 0.42 0.14
Amortization Expense
0.42 0.42 1.07 0.98 0.73 0.73
Non-Cash Adjustments To Reconcile Net Income
0.74 1.98 -11 4.94 0.13 -0.21
Changes in Operating Assets and Liabilities, net
-2.69 8.48 -6.00 -11 6.21 -3.48
Net Cash From Investing Activities
0.00 -0.01 -5.16 0.62 -0.00 3.00
Net Cash From Continuing Investing Activities
0.00 -0.01 -5.16 0.62 -0.00 3.00
Purchase of Property, Plant & Equipment
0.00 -0.01 -0.04 -0.01 -0.01 -0.00
Acquisitions
- - - 0.00 -0.05 0.00
Sale of Property, Plant & Equipment
- - - - 0.00 3.00
Sale and/or Maturity of Investments
- - 0.00 0.62 0.06 0.00
Net Cash From Financing Activities
13 43 14 8.41 15 11
Net Cash From Continuing Financing Activities
13 43 14 8.41 15 11
Repayment of Debt
8.79 - 0.00 -21 -0.27 0.00
Repurchase of Preferred Equity
- - - 0.00 7.66 0.00
Issuance of Debt
- - 0.00 25 7.44 0.00
Issuance of Preferred Equity
- - - 0.00 0.00 11
Cash Interest Paid
3.07 0.00 0.00 0.15 1.73 0.01
Cash Income Taxes Paid
0.06 0.06 0.03 0.02 0.02 0.03

Quarterly Cash Flow Statements for Biofrontera

This table details how cash moves in and out of Biofrontera's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
2.47 0.56 -1.51 3.03 -4.12 5.45 -3.82 2.98 -0.08 -1.66 -1.44
Net Cash From Operating Activities
-3.33 -4.72 -1.21 -1.02 -4.12 -3.05 -3.82 -2.38 -0.07 -1.66 -1.43
Net Cash From Continuing Operating Activities
-3.33 -4.72 -1.21 -1.02 -4.12 -3.05 -3.82 -2.38 -0.07 -1.66 -1.43
Net Income / (Loss) Continuing Operations
-10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75 -0.60 -6.42
Consolidated Net Income / (Loss)
-10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75 -0.60 -6.42
Depreciation Expense
0.02 0.02 0.02 0.36 0.03 0.02 0.02 0.07 0.06 0.07 0.06
Non-Cash Adjustments To Reconcile Net Income
4.19 -5.45 1.36 0.03 -0.24 0.14 0.73 -0.85 0.69 0.34 1.37
Changes in Operating Assets and Liabilities, net
2.62 0.67 2.79 0.13 0.10 1.92 1.89 -7.39 3.80 -1.59 3.82
Net Cash From Investing Activities
0.00 -0.00 - -0.00 -0.00 -0.00 0.00 3.00 -0.01 - -0.01
Net Cash From Continuing Investing Activities
0.00 -0.00 - -0.00 -0.00 -0.00 0.00 3.00 -0.01 - -0.01
Purchase of Property, Plant & Equipment
-0.06 -0.00 - 0.05 -0.00 -0.00 0.00 0.00 -0.01 - -0.01

Annual Balance Sheets for Biofrontera

This table presents Biofrontera's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
24 53 51 28 22 29
Total Current Assets
20 46 43 23 21 18
Cash & Equivalents
8.08 25 17 1.34 5.91 6.39
Short-Term Investments
- 0.00 11 0.08 0.01 0.01
Accounts Receivable
3.29 12 7.41 5.16 5.32 7.29
Inventories, net
7.09 4.46 7.17 11 6.65 1.43
Prepaid Expenses
1.12 4.99 0.81 0.43 0.53 2.28
Other Current Assets
- - 0.00 5.16 2.30 0.70
Plant, Property, & Equipment, net
0.37 0.27 0.20 0.13 0.08 2.16
Total Noncurrent Assets
4.19 6.53 7.54 4.72 1.32 8.32
Intangible Assets
3.87 3.45 3.03 2.63 0.04 2.65
Other Noncurrent Operating Assets
0.32 0.27 1.70 2.09 1.29 5.67
Total Liabilities & Shareholders' Equity
24 53 51 28 22 29
Total Liabilities
18 42 27 23 18 18
Total Current Liabilities
4.42 14 21 18 12 12
Accounts Payable
4.42 11 13 13 11 12
Other Current Liabilities
0.00 0.00 0.50 0.69 0.55 0.33
Total Noncurrent Liabilities
14 28 6.11 5.05 5.65 6.19
Long-Term Debt
- - - 0.00 4.10 4.59
Other Noncurrent Operating Liabilities
14 28 6.11 5.05 1.55 1.60
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
5.83 11 24 4.79 4.43 10
Total Preferred & Common Equity
5.83 11 24 4.79 4.43 10
Preferred Stock
- 0.00 0.00 0.00 0.00 0.00
Total Common Equity
5.83 11 24 4.79 4.43 10
Common Stock
47 90 103 104 122 138
Retained Earnings
-41 -79 -80 -100 -117 -128

Quarterly Balance Sheets for Biofrontera

This table presents Biofrontera's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
34 25 22 19 17 20 15 25 24 21
Total Current Assets
30 20 17 17 15 19 14 13 12 11
Cash & Equivalents
3.42 3.82 4.38 2.87 1.79 7.24 3.42 6.32 4.66 3.22
Short-Term Investments
3.34 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Accounts Receivable
6.51 3.69 3.50 4.87 4.03 3.96 3.00 3.88 5.55 4.79
Inventories, net
16 6.91 3.95 6.53 6.53 4.03 4.33 1.23 1.10 1.73
Prepaid Expenses
0.27 0.56 0.47 0.35 0.68 0.33 0.63 1.06 0.89 1.11
Other Current Assets
- 5.16 5.16 2.30 2.30 3.25 3.03 0.66 0.23 0.24
Plant, Property, & Equipment, net
0.15 0.12 0.10 0.08 0.06 0.04 0.02 2.18 2.14 2.11
Total Noncurrent Assets
4.34 4.30 4.00 1.50 1.20 1.29 0.98 9.45 9.49 8.25
Intangible Assets
2.72 2.56 2.45 0.04 0.03 0.03 0.02 2.61 2.57 2.53
Other Noncurrent Operating Assets
1.62 1.74 1.55 1.46 1.17 1.26 0.96 6.84 6.92 5.72
Total Liabilities & Shareholders' Equity
34 25 22 19 17 20 15 25 24 21
Total Liabilities
33 26 11 13 16 25 18 19 18 22
Total Current Liabilities
29 14 9.27 11 11 20 13 11 11 14
Accounts Payable
20 11 8.27 10 11 11 12 10 10 14
Other Current Liabilities
0.56 0.69 0.70 0.67 0.43 8.94 0.31 0.51 0.47 0.46
Total Noncurrent Liabilities
3.94 12 1.40 1.95 5.16 5.12 5.44 7.79 7.57 7.47
Long-Term Debt
- - - - 4.22 4.34 4.46 4.72 4.62 4.75
Other Noncurrent Operating Liabilities
3.94 12 1.40 1.95 0.94 0.79 0.98 3.08 2.95 2.72
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1.04 -5.42 11 5.53 0.47 -4.67 -2.58 6.07 5.96 -0.24
Total Preferred & Common Equity
1.04 -5.42 11 5.53 0.47 -4.67 -2.58 6.07 5.96 -0.24
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1.04 -5.42 11 5.53 0.47 -4.67 -2.58 6.07 5.96 -0.24
Common Stock
104 105 121 122 122 122 131 139 139 139
Retained Earnings
-103 -110 -110 -116 -122 -127 -134 -133 -133 -140

Annual Metrics And Ratios for Biofrontera

This table displays calculated financial ratios and metrics derived from Biofrontera's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 11,600,000.00 26,699,002.00 1,517,628.00 7,749,211.00 11,648,323.00
DEI Adjusted Shares Outstanding
0.00 580,000.00 1,334,950.00 1,517,628.00 7,749,211.00 11,648,323.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -65.02 -0.48 -13.26 -2.29 -0.90
Growth Metrics
- - - - - -
Revenue Growth
0.00% 27.86% 18.98% 18.82% 9.54% 11.75%
EBITDA Growth
0.00% -390.83% 97.31% -1,029.96% -27.40% 35.37%
EBIT Growth
0.00% -363.29% 94.21% -466.11% -25.71% 34.55%
NOPAT Growth
0.00% -162.35% 26.27% -22.04% 24.11% 34.06%
Net Income Growth
0.00% -243.25% 98.30% -3,045.47% 11.78% 40.67%
EPS Growth
0.00% 0.00% 0.00% -2,034.43% 75.27% 67.70%
Operating Cash Flow Growth
0.00% -115.98% 39.36% -53.68% 58.75% -30.10%
Free Cash Flow Firm Growth
0.00% 0.00% -162.25% 22.85% 63.21% -89.35%
Invested Capital Growth
0.00% -342.50% 130.75% 137.47% -64.00% 230.97%
Revenue Q/Q Growth
0.00% 0.00% 3.53% 1.34% 5.55% 12.22%
EBITDA Q/Q Growth
0.00% 0.00% 91.45% 43.32% -71.90% 43.63%
EBIT Q/Q Growth
0.00% 0.00% 82.11% 42.43% -61.86% 41.43%
NOPAT Q/Q Growth
0.00% 0.00% -25.19% 7.18% 11.12% 35.58%
Net Income Q/Q Growth
0.00% 0.00% 94.82% 23.87% -38.34% 40.04%
EPS Q/Q Growth
0.00% 0.00% 94.82% 32.71% -45.05% 36.20%
Operating Cash Flow Q/Q Growth
0.00% -318.21% 43.98% -2.45% 43.32% -11.32%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 8.56% 43.24% -71.98%
Invested Capital Q/Q Growth
0.00% 0.00% 282.27% 128.59% -1.13% 660.67%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 100.00% 48.80% 50.14% 73.71%
EBITDA Margin
-39.75% -152.59% -3.45% -32.77% -38.11% -22.04%
Operating Margin
-50.96% -104.57% -64.80% -66.56% -46.11% -27.21%
EBIT Margin
-42.73% -154.83% -7.53% -35.89% -41.19% -24.12%
Profit (Net Income) Margin
-58.29% -156.49% -2.23% -59.09% -47.58% -25.26%
Tax Burden Percent
100.59% 100.15% 105.26% 100.07% 100.12% 100.24%
Interest Burden Percent
135.62% 100.92% 28.15% 164.52% 115.39% 104.47%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -307.04% -243.50% -140.76%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -260.59% -1,951.12% 2.23%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 166.61% -141.48% -0.54%
Return on Equity (ROE)
-188.52% -439.39% -3.63% -140.43% -384.98% -141.30%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -849.73% -388.51% -149.37% -247.94%
Operating Return on Assets (OROA)
-33.37% -96.47% -4.15% -31.03% -61.45% -39.72%
Return on Assets (ROA)
-45.52% -97.50% -1.23% -51.08% -70.99% -41.59%
Return on Common Equity (ROCE)
-188.52% -439.39% -3.63% -140.43% -384.98% -141.30%
Return on Equity Simple (ROE_SIMPLE)
-188.52% -332.62% -2.68% -420.01% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.72 -18 -13 -16 -12 -7.94
NOPAT Margin
-35.67% -73.20% -45.36% -46.59% -32.28% -19.05%
Net Nonoperating Expense Percent (NNEP)
-52.76% -136.63% 58.73% -46.45% 1,707.62% -142.99%
Return On Investment Capital (ROIC_SIMPLE)
- - - -182.52% -141.21% -52.71%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 51.20% 49.86% 26.29%
SG&A Expenses to Revenue
93.94% 154.39% 122.54% 114.84% 90.66% 92.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.23% 5.60% 8.92%
Operating Expenses to Revenue
150.96% 204.57% 164.80% 115.36% 96.26% 100.92%
Earnings before Interest and Taxes (EBIT)
-8.05 -37 -2.16 -12 -15 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.49 -37 -0.99 -11 -14 -9.19
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
3.09 7.69 1.02 0.88 1.91 0.63
Price to Tangible Book Value (P/TBV)
9.19 11.06 1.17 1.94 1.92 0.85
Price to Revenue (P/Rev)
0.96 3.62 0.85 0.12 0.23 0.16
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 1.19 0.92 2.53 0.56
Enterprise Value to Revenue (EV/Rev)
0.53 2.74 0.13 0.20 0.18 0.12
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.29 0.29 0.81 0.92 0.44
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.92 0.44
Financial Leverage
-1.39 -1.71 -1.20 -0.64 0.07 -0.24
Leverage Ratio
4.14 4.51 2.96 2.75 5.42 3.40
Compound Leverage Factor
5.62 4.55 0.83 4.52 6.26 3.55
Debt to Total Capital
0.00% 22.24% 22.52% 44.89% 48.04% 30.45%
Short-Term Debt to Total Capital
0.00% 22.24% 22.52% 44.89% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 48.04% 30.45%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 77.76% 77.48% 55.11% 51.96% 69.55%
Debt to EBITDA
0.00 -0.09 -7.03 -0.35 -0.29 -0.50
Net Debt to EBITDA
0.00 0.58 21.07 -0.22 0.13 0.20
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 -0.29 -0.50
Debt to NOPAT
0.00 -0.18 -0.53 -0.25 -0.34 -0.58
Net Debt to NOPAT
0.00 1.21 1.60 -0.16 0.15 0.23
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 -0.34 -0.58
Altman Z-Score
-1.36 -1.95 -0.70 -4.90 -7.29 -5.49
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
4.43 3.36 2.06 1.28 1.72 1.52
Quick Ratio
2.57 2.67 1.68 0.36 0.93 1.15
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -9.93 -26 -20 -7.39 -14
Operating Cash Flow to CapEx
0.00% -242,863.64% -42,628.95% -497,900.00% -102,700.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -28.86 -133.52 0.00 -23.39 0.00
Operating Cash Flow to Interest Expense
-4.31 -77.66 -83.07 0.00 -32.50 0.00
Operating Cash Flow Less CapEx to Interest Expense
-4.31 -77.69 -83.27 0.00 -32.53 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.78 0.62 0.55 0.86 1.49 1.65
Accounts Receivable Turnover
5.73 3.07 2.89 5.42 7.12 6.62
Inventory Turnover
0.00 0.00 0.00 1.93 2.12 2.72
Fixed Asset Turnover
50.94 75.67 121.76 201.60 348.79 37.27
Accounts Payable Turnover
0.00 0.00 0.00 1.29 1.49 0.95
Days Sales Outstanding (DSO)
63.69 119.04 126.26 67.32 51.23 55.16
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 189.11 172.17 134.36
Days Payable Outstanding (DPO)
0.00 0.00 0.00 281.92 244.87 383.44
Cash Conversion Cycle (CCC)
63.69 119.04 126.26 -25.49 -21.47 -193.92
Capital & Investment Metrics
- - - - - -
Invested Capital
-2.25 -9.97 3.06 7.28 2.62 8.67
Invested Capital Turnover
-8.37 -3.95 -8.31 6.59 7.54 7.39
Increase / (Decrease) in Invested Capital
0.00 -7.71 13 4.21 -4.66 6.05
Enterprise Value (EV)
9.92 66 3.66 6.69 6.63 4.83
Market Capitalization
18 87 24 4.20 8.45 6.64
Book Value per Share
$0.25 $0.98 $0.89 $3.16 $0.57 $0.90
Tangible Book Value per Share
$0.09 $0.68 $0.78 $1.43 $0.57 $0.67
Total Capital
5.83 15 31 8.70 8.53 15
Total Debt
0.00 3.24 6.94 3.90 4.10 4.59
Total Long-Term Debt
0.00 0.00 0.00 0.00 4.10 4.59
Net Debt
-8.08 -21 -21 2.48 -1.81 -1.81
Capital Expenditures (CapEx)
0.00 0.01 0.04 0.01 0.01 -3.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
7.08 11 1.43 7.47 2.77 -0.21
Debt-free Net Working Capital (DFNWC)
15 36 29 8.89 8.68 6.19
Net Working Capital (NWC)
15 33 22 4.99 8.68 6.19
Net Nonoperating Expense (NNE)
4.26 20 -12 4.26 5.71 2.59
Net Nonoperating Obligations (NNO)
-8.08 -21 -21 2.48 -1.81 -1.81
Total Depreciation and Amortization (D&A)
0.56 0.54 1.17 1.06 1.15 0.87
Debt-free, Cash-free Net Working Capital to Revenue
37.54% 46.81% 4.99% 21.92% 7.41% -0.51%
Debt-free Net Working Capital to Revenue
80.41% 148.66% 101.79% 26.10% 23.26% 14.84%
Net Working Capital to Revenue
80.41% 135.21% 77.58% 14.64% 23.26% 14.84%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($85.60) ($0.60) ($13.02) ($3.22) ($1.04)
Adjusted Weighted Average Basic Shares Outstanding
0.00 440.41K 1.06M 1.55M 5.52M 10.17M
Adjusted Diluted Earnings per Share
$0.00 ($85.60) $0.00 ($13.02) ($3.22) ($1.04)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 440.41K 1.33M 1.55M 5.52M 10.17M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($85.60) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 440.41K 1.33M 5.09M 8.87M 11.65M
Normalized Net Operating Profit after Tax (NOPAT)
-5.83 -18 -16 -16 -12 -7.94
Normalized NOPAT Margin
-30.95% -75.09% -54.64% -46.39% -32.28% -19.05%
Pre Tax Income Margin
-57.95% -156.25% -2.12% -59.04% -47.53% -25.20%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-2.81 -108.47 -11.08 0.00 -48.65 0.00
NOPAT to Interest Expense
-2.34 -51.28 -66.70 0.00 -38.12 0.00
EBIT Less CapEx to Interest Expense
-2.81 -108.50 -11.27 0.00 -48.68 0.00
NOPAT Less CapEx to Interest Expense
-2.34 -51.31 -66.90 0.00 -38.16 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Biofrontera

This table displays calculated financial ratios and metrics derived from Biofrontera's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
5,089,413.00 5,089,413.00 5,543,518.00 7,749,211.00 8,873,932.00 9,446,197.00 10,668,442.00 11,648,323.00 11,648,323.00 12,803,344.00 14,852,359.00
DEI Adjusted Shares Outstanding
5,089,413.00 5,089,413.00 5,543,518.00 7,749,211.00 8,873,932.00 9,446,197.00 10,668,442.00 11,648,323.00 11,648,323.00 12,803,344.00 14,852,359.00
DEI Earnings Per Adjusted Shares Outstanding
-2.05 -0.05 -1.02 -0.18 -0.47 -0.56 -0.62 0.48 -0.41 -0.05 -0.43
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-9.40% 34.05% 1.30% 18.54% 8.54% 15.19% -22.46% 36.16% 17.42% 32.92% 29.79%
EBITDA Growth
-98.75% 108.51% -43.47% -123.60% 53.87% -828.45% -18.02% 626.41% -14.46% 94.81% 1.42%
EBIT Growth
-93.82% 104.51% -42.26% -130.04% 52.98% -1,491.42% -15.18% 524.47% -12.91% 91.25% 3.64%
NOPAT Growth
0.46% 41.71% -7.36% 69.05% 16.83% -0.16% -26.57% 480.24% 4.99% 89.68% -3.49%
Net Income Growth
-39.57% 97.39% 10.61% -139.59% 59.73% -1,971.60% -17.29% 504.01% -13.06% 88.66% 3.40%
EPS Growth
0.00% 99.31% 78.88% -110.96% 83.68% -1,040.00% 36.73% 348.00% 12.77% 91.23% 32.26%
Operating Cash Flow Growth
9.87% 54.33% 39.72% 88.53% -23.82% 35.49% -216.47% -133.63% 98.30% 45.55% 62.54%
Free Cash Flow Firm Growth
118.95% 101.72% 63.72% 142.78% -530.35% 1,891.68% 93.21% -143.14% 51.18% -227.79% -3,592.33%
Invested Capital Growth
-224.20% -37.52% -16.78% -64.00% 186.88% -211.15% -158.36% 230.97% 54.22% 177.98% 182.54%
Revenue Q/Q Growth
-25.32% -0.92% 14.96% 39.35% -31.61% 5.15% -22.61% 144.69% -41.03% 19.03% -24.44%
EBITDA Q/Q Growth
-274.71% 108.11% -885.92% 78.81% -241.46% -28.07% -27.33% 194.53% -174.25% 94.19% -2,317.05%
EBIT Q/Q Growth
-292.92% 104.28% -1,620.64% 76.08% -201.99% -26.65% -25.88% 188.17% -180.33% 90.19% -1,286.56%
NOPAT Q/Q Growth
1.18% 7.24% 2.19% 65.48% -165.60% -11.70% -23.61% 203.69% -166.36% 87.87% -1,139.89%
Net Income Q/Q Growth
-396.00% 97.54% -2,105.84% 75.37% -201.07% -26.67% -24.89% 184.82% -184.26% 87.29% -963.41%
EPS Q/Q Growth
-226.32% 98.26% -1,860.00% 74.49% -88.00% -21.28% -8.77% 200.00% -166.13% 87.80% -740.00%
Operating Cash Flow Q/Q Growth
62.50% -41.95% 74.41% 15.81% -304.82% 26.04% -25.55% 37.85% 97.05% -2,268.57% 13.63%
Free Cash Flow Firm Q/Q Growth
127.04% -75.10% -639.78% 217.72% -372.01% 215.23% -101.84% -647.59% -207.80% -201.63% 46.80%
Invested Capital Q/Q Growth
-145.78% 304.68% -61.15% -1.13% 10.50% -361.85% 79.60% 660.67% -48.51% 32.40% -78.41%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
47.98% 44.61% 45.88% 58.02% 61.95% 70.74% 70.74% 82.40% 79.02% 79.92% 74.41%
EBITDA Margin
-106.28% 8.70% -59.48% -9.05% -45.17% -55.02% -90.53% 34.97% -44.03% -2.15% -68.75%
Operating Margin
-69.10% -64.69% -55.04% -13.63% -52.95% -56.25% -89.84% 26.64% -42.84% -4.37% -71.63%
EBIT Margin
-110.16% 4.76% -62.94% -10.81% -47.72% -57.48% -93.49% 33.69% -45.88% -3.78% -69.40%
Profit (Net Income) Margin
-131.91% -3.28% -62.91% -11.12% -48.94% -58.96% -95.15% 32.98% -47.12% -5.03% -70.82%
Tax Burden Percent
100.01% 108.44% 100.05% 99.86% 99.98% 100.40% 100.09% 100.02% 100.00% 103.96% 100.06%
Interest Burden Percent
119.73% -63.54% 99.89% 103.02% 102.59% 102.18% 101.68% 97.90% 102.70% 127.97% 101.97%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -180.01% -467.14% -71.99% 0.00% 0.00% -4,237.83% 196.94% -352.19% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -2,040.29% 129.87% -131.06% 0.00% 0.00% -3,993.58% 137.19% -774.68% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 39.94% -14.55% -9.50% 0.00% 0.00% 2,499.88% -33.36% -96.91% 0.00% 0.00%
Return on Equity (ROE)
-309.83% -140.07% -481.69% -81.49% 1,673.93% -531.54% -1,737.95% 163.58% -449.09% -988.35% 434.77%
Cash Return on Invested Capital (CROIC)
0.00% -104.04% -446.53% -149.37% -609.12% 0.00% 0.00% -247.94% -254.28% -306.03% -593.38%
Operating Return on Assets (OROA)
-110.10% 5.73% -84.58% -16.12% -88.10% -107.98% -204.79% 55.46% -95.82% -7.90% -181.62%
Return on Assets (ROA)
-131.83% -3.95% -84.54% -16.58% -90.35% -110.77% -208.43% 54.30% -98.41% -10.51% -185.31%
Return on Common Equity (ROCE)
-235.62% -140.07% -481.69% -81.49% 6,013.74% -531.54% -1,737.95% 163.58% -449.09% -988.35% 434.77%
Return on Equity Simple (ROE_SIMPLE)
426.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.83 -3.55 -3.47 -1.20 -3.18 -3.56 -4.39 4.56 -3.02 -0.37 -4.55
NOPAT Margin
-48.37% -45.28% -38.53% -9.54% -37.06% -39.37% -62.89% 26.65% -29.99% -3.06% -50.14%
Net Nonoperating Expense Percent (NNEP)
-85.00% 1,860.28% -597.01% 59.07% 217.04% -50.51% -244.25% 59.75% 422.49% -16.04% 146.84%
Return On Investment Capital (ROIC_SIMPLE)
125.02% -31.67% -62.78% -14.05% -67.92% 1,077.36% -233.63% 30.24% -28.03% -3.47% -100.93%
Cost of Revenue to Revenue
52.02% 55.39% 54.12% 41.98% 38.05% 29.26% 29.26% 17.60% 20.98% 20.08% 25.59%
SG&A Expenses to Revenue
116.86% 101.38% 93.50% 65.42% 100.84% 117.35% 148.35% 51.19% 109.04% 80.55% 137.71%
R&D to Revenue
0.21% 7.92% 7.42% 6.23% 14.05% 9.63% 12.22% 4.61% 8.93% 3.73% 4.96%
Operating Expenses to Revenue
117.08% 109.30% 100.92% 71.65% 114.89% 126.99% 160.58% 55.80% 121.86% 84.29% 146.04%
Earnings before Interest and Taxes (EBIT)
-8.72 0.37 -5.67 -1.36 -4.10 -5.19 -6.53 5.76 -4.63 -0.45 -6.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-8.41 0.68 -5.36 -1.14 -3.88 -4.97 -6.33 5.98 -4.44 -0.26 -6.24
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.42 1.33 1.91 15.14 0.00 0.00 0.63 1.55 2.03 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.54 1.34 1.92 16.21 0.00 0.00 0.85 2.72 3.57 0.00
Price to Revenue (P/Rev)
0.24 0.13 0.21 0.23 0.19 0.17 0.28 0.16 0.22 0.26 0.33
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.07 1.70 2.53 3.29 0.00 0.00 0.56 1.75 2.04 13.76
Enterprise Value to Revenue (EV/Rev)
0.30 0.01 0.13 0.18 0.25 0.10 0.31 0.12 0.18 0.26 0.36
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 1.28 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-1.28 0.03 0.00 0.92 8.99 -0.93 -1.73 0.44 0.78 0.78 -19.54
Long-Term Debt to Equity
0.00 0.00 0.00 0.92 8.99 -0.93 -1.73 0.44 0.78 0.78 -19.54
Financial Leverage
-1.04 -0.02 -0.11 0.07 -0.68 -1.12 -0.63 -0.24 0.13 -2.30 -0.90
Leverage Ratio
4.46 3.23 8.01 5.42 -29.89 6.68 11.51 3.40 6.33 34.32 -13.06
Compound Leverage Factor
5.35 -2.05 8.00 5.59 -30.67 6.83 11.70 3.33 6.50 43.92 -13.32
Debt to Total Capital
462.67% 2.64% 0.00% 48.04% 89.99% -1,314.55% 237.21% 30.45% 43.74% 43.68% 105.39%
Short-Term Debt to Total Capital
462.67% 2.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 48.04% 89.99% -1,314.55% 237.21% 30.45% 43.74% 43.68% 105.39%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
701.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-1,064.05% 97.36% 100.00% 51.96% 10.01% 1,414.55% -137.21% 69.55% 56.26% 56.32% -5.39%
Debt to EBITDA
-0.15 -0.04 0.00 -0.29 -0.44 -0.28 -0.27 -0.50 -0.48 -0.92 -0.88
Net Debt to EBITDA
0.10 0.62 0.00 0.13 -0.25 0.19 -0.06 0.20 0.16 0.01 -0.28
Long-Term Debt to EBITDA
0.00 0.00 0.00 -0.29 -0.44 -0.28 -0.27 -0.50 -0.48 -0.92 -0.88
Debt to NOPAT
-0.15 -0.02 0.00 -0.34 -0.37 -0.38 -0.36 -0.58 -0.61 -1.01 -1.00
Net Debt to NOPAT
0.09 0.31 0.00 0.15 -0.21 0.26 -0.08 0.23 0.21 0.01 -0.32
Long-Term Debt to NOPAT
0.00 0.00 0.00 -0.34 -0.37 -0.38 -0.36 -0.58 -0.61 -1.01 -1.00
Altman Z-Score
-5.61 -4.76 -7.15 -5.19 -8.21 -7.62 -10.62 -3.67 -5.96 -5.40 -7.56
Noncontrolling Interest Sharing Ratio
23.95% 0.00% 0.00% 0.00% -259.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.44 1.89 1.53 1.72 1.40 0.96 1.15 1.52 1.20 1.18 0.78
Quick Ratio
0.54 0.85 0.70 0.93 0.53 0.57 0.51 1.15 0.93 0.97 0.56
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2.19 0.54 -2.94 3.46 -9.41 11 -0.20 -1.49 -4.59 -14 -7.37
Operating Cash Flow to CapEx
-5,833.33% -236,000.00% 0.00% 0.00% -137,233.33% -304,500.00% 0.00% 0.00% -1,400.00% 0.00% -15,911.11%
Free Cash Flow to Firm to Interest Expense
6.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-10.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-10.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.00 1.21 1.34 1.49 1.85 1.88 2.19 1.65 2.09 2.09 2.62
Accounts Receivable Turnover
5.75 7.27 6.21 7.12 9.84 10.51 9.45 6.62 10.92 9.72 12.40
Inventory Turnover
2.50 1.97 1.66 2.12 2.64 4.03 2.44 2.72 2.53 3.74 3.25
Fixed Asset Turnover
209.78 255.37 299.64 348.79 424.55 567.94 728.71 37.27 38.68 42.44 45.27
Accounts Payable Turnover
1.42 1.48 1.25 1.49 1.65 1.69 1.17 0.95 0.94 0.92 0.76
Days Sales Outstanding (DSO)
63.43 50.22 58.74 51.23 37.09 34.74 38.64 55.16 33.42 37.55 29.43
Days Inventory Outstanding (DIO)
146.06 185.62 220.47 172.17 138.03 90.62 149.77 134.36 144.30 97.63 112.25
Days Payable Outstanding (DPO)
257.42 246.82 292.96 244.87 221.19 216.09 311.93 383.44 389.66 396.49 481.80
Cash Conversion Cycle (CCC)
-47.93 -10.98 -13.75 -21.47 -46.07 -90.74 -123.52 -193.92 -211.95 -261.31 -340.12
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-3.33 6.82 2.65 2.62 2.89 -7.58 -1.55 8.67 4.46 5.91 1.28
Invested Capital Turnover
-102.47 3.98 12.13 7.54 -173.90 -103.13 67.39 7.39 11.74 -55.33 -357.45
Increase / (Decrease) in Invested Capital
-6.01 -4.09 -0.53 -4.66 6.23 -14 -4.20 6.05 1.57 13 2.82
Enterprise Value (EV)
9.92 0.48 4.49 6.63 9.52 3.81 12 4.83 7.82 12 18
Market Capitalization
7.84 4.57 7.37 8.45 7.10 6.72 11 6.64 9.42 12 16
Book Value per Share
($1.06) $2.14 $1.00 $0.57 $0.05 ($0.49) ($0.24) $0.90 $0.52 $0.47 ($0.02)
Tangible Book Value per Share
($1.57) $1.66 $0.99 $0.57 $0.05 ($0.50) ($0.24) $0.67 $0.30 $0.26 ($0.19)
Total Capital
0.51 11 5.53 8.53 4.69 -0.33 1.88 15 11 11 4.51
Total Debt
2.36 0.30 0.00 4.10 4.22 4.34 4.46 4.59 4.72 4.62 4.75
Total Long-Term Debt
0.00 0.00 0.00 4.10 4.22 4.34 4.46 4.59 4.72 4.62 4.75
Net Debt
-1.49 -4.09 -2.88 -1.81 2.43 -2.91 1.04 -1.81 -1.61 -0.05 1.52
Capital Expenditures (CapEx)
0.06 0.00 0.00 -0.05 0.00 0.00 -0.00 -0.00 0.01 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
4.63 4.11 3.02 2.77 2.58 -8.12 -1.57 -0.21 -4.09 -2.77 -6.36
Debt-free Net Working Capital (DFNWC)
8.47 8.50 5.90 8.68 4.37 -0.87 1.86 6.19 2.24 1.89 -3.13
Net Working Capital (NWC)
6.12 8.20 5.90 8.68 4.37 -0.87 1.86 6.19 2.24 1.89 -3.13
Net Nonoperating Expense (NNE)
6.61 -3.29 2.20 0.20 1.02 1.77 2.25 -1.08 1.73 0.24 1.88
Net Nonoperating Obligations (NNO)
-1.49 -4.09 -2.88 -1.81 2.43 -2.91 1.04 -1.81 -1.61 -0.05 1.52
Total Depreciation and Amortization (D&A)
0.31 0.31 0.31 0.22 0.22 0.22 0.21 0.22 0.19 0.20 0.06
Debt-free, Cash-free Net Working Capital to Revenue
13.94% 11.66% 8.54% 7.41% 6.79% -20.72% -4.22% -0.51% -9.47% -6.01% -13.19%
Debt-free Net Working Capital to Revenue
25.49% 24.12% 16.68% 23.26% 11.51% -2.23% 5.00% 14.84% 5.18% 4.10% -6.49%
Net Working Capital to Revenue
18.40% 23.28% 16.68% 23.26% 11.51% -2.23% 5.00% 14.84% 5.18% 4.10% -6.49%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41) ($0.05) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding
5.09M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M 12.92M 15.28M
Adjusted Diluted Earnings per Share
$0.00 ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41) ($0.05) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding
5.09M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M 12.92M 15.28M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.25) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
5.09M 5.54M 7.75M 8.87M 9.45M 10.67M 11.65M 11.65M 12.80M 14.85M 17.95M
Normalized Net Operating Profit after Tax (NOPAT)
-3.83 -3.55 -3.47 -1.20 -3.18 -3.56 -4.39 3.19 -3.02 -0.37 -4.55
Normalized NOPAT Margin
-48.37% -45.28% -38.53% -9.54% -37.06% -39.37% -62.89% 18.65% -29.99% -3.06% -50.14%
Pre Tax Income Margin
-131.90% -3.02% -62.87% -11.13% -48.95% -58.73% -95.06% 32.98% -47.12% -4.84% -70.77%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-27.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-12.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-27.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-12.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Biofrontera’s latest results show meaningful operational improvement, but the company remains unprofitable and continues to consume cash. Revenue increased to $12.0 million in Q2 2026, up from $9.0 million in the restated Q2 2025 results and $10.1 million in Q1 2026. The company’s gross margin remained strong at approximately 80%, compared with about 71% in Q2 2025, although higher operating expenses still resulted in a net loss.

  • Revenue growth accelerated: Q2 2026 revenue rose approximately 33% year over year and 19% sequentially. Q1 2026 revenue was also up about 17% year over year.
  • Gross profit improved substantially: Q2 gross profit increased to $9.6 million from $6.4 million a year earlier. The gross margin expanded to roughly 80% from 71%, indicating better product economics or sales mix.
  • Operating losses narrowed sharply: The Q2 operating loss was $524,000, compared with a $5.1 million loss in Q2 2025 and a $4.3 million loss in Q1 2026.
  • Net losses are improving: Q2 2026 net loss declined to $604,000, or $0.05 per share, compared with a $5.3 million loss, or $0.57 per share, in the restated Q2 2025 results.
  • Cash-flow performance improved year over year: Operating cash outflow decreased to $1.7 million in Q2 2026 from $3.0 million in Q2 2025. This was also an improvement from the $4.1 million operating cash outflow in Q1 2025.
  • Working-capital assets strengthened in some areas: Accounts receivable increased to $5.5 million from $3.9 million at the end of Q1 2026, consistent with the quarter’s higher revenue. Inventory also declined to $1.1 million from $1.2 million in Q1 and $4.0 million a year earlier.
  • Liquidity remains limited but positive: Biofrontera held $4.7 million of cash and cash equivalents at June 30, 2026, plus $8,000 of short-term investments. Current assets of $12.4 million exceeded current liabilities of $10.5 million, producing a current ratio of approximately 1.2.
  • Q4 2025 profitability was not representative of the current trend: The company reported $5.6 million of net income in Q4 2025, but that quarter included substantial other income. Biofrontera returned to losses in Q1 and Q2 2026, so investors should focus on operating results rather than the isolated Q4 profit.
  • Biofrontera is still burning cash: Operating cash flow remained negative in both Q1 and Q2 2026, with $1.7 million of cash used in operations during Q2. At the latest quarterly burn rate, the company’s cash balance provides limited financial flexibility without further improvement or outside funding.
  • Balance-sheet risk remains elevated: Accounts payable totaled $10.1 million, more than twice the company’s cash balance. Total liabilities of $18.1 million also substantially exceeded cash, while retained earnings were negative $133.3 million.
  • Share dilution is a concern: Weighted average basic shares increased to 12.9 million in Q2 2026 from 9.4 million in the restated Q2 2025 results. Additional equity financing could provide liquidity but would dilute existing shareholders.
  • Operating expenses remain high: Selling, general and administrative expense was $9.7 million in Q2 2026, nearly equal to gross profit. The company also continues to report quarterly research and development spending, making sustained profitability dependent on further revenue growth and cost control.

Overall, the statements point to a constructive improvement in revenue, gross margin and operating losses. However, Biofrontera has not yet achieved consistent profitability, and its negative operating cash flow, sizable accounts payable balance and rising share count remain significant risks for investors.

11/16/26 11:17 AM ETAI Generated. May Contain Errors.

Biofrontera Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Biofrontera's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Biofrontera's net income appears to be on an upward trend, with a most recent value of -$10.54 million in 2025, rising from -$10.99 million in 2020. The previous period was -$17.76 million in 2024.

Biofrontera's total operating income in 2025 was -$11.35 million, based on the following breakdown:
  • Total Gross Profit: $30.74 million
  • Total Operating Expenses: $42.09 million

Over the last 5 years, Biofrontera's total revenue changed from $18.85 million in 2020 to $41.71 million in 2025, a change of 121.3%.

In the past 12 quarters, Biofrontera's cash and equivalents has ranged from $1.79 million in Q1 2025 to $7.24 million in Q2 2025, and is currently $3.22 million as of their latest financial filing in Q3 2026.

Biofrontera had total debt of $4.59 million at the end of 2025, a 12.0% increase from 2024, and none in 2020.

Over the last 5 years, Biofrontera's book value per share changed from 0.25 in 2020 to 0.90 in 2025, a change of 253.8%.



Financial statements for NASDAQ:BFRIW last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners